239 related articles for article (PubMed ID: 19672945)
1. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Wolff D; Poniewierski MS; Dale DC; Crawford J; Lyman GH
Cancer; 2009 Nov; 115(22):5319-28. PubMed ID: 19672945
[TBL] [Abstract][Full Text] [Related]
2. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
3. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
[TBL] [Abstract][Full Text] [Related]
4. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
Khan S; Dhadda A; Fyfe D; Sundar S
Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
[TBL] [Abstract][Full Text] [Related]
5. Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients.
Garg P; Rana F; Gupta R; Buzaianu EM; Guthrie TH
Breast J; 2009; 15(4):404-8. PubMed ID: 19508671
[TBL] [Abstract][Full Text] [Related]
6. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
Repetto L;
Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
[TBL] [Abstract][Full Text] [Related]
7. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
Chirivella I; Bermejo B; Insa A; Pérez-Fidalgo A; Magro A; Rosello S; García-Garre E; Martín P; Bosch A; Lluch A
Breast Cancer Res Treat; 2009 Apr; 114(3):479-84. PubMed ID: 18463977
[TBL] [Abstract][Full Text] [Related]
8. Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.
Koutras AK; Fountzilas G; Dafni U; Dimopoulos MA; Pectasides D; Klouvas G; Papakostas P; Kosmidis P; Samantas E; Gogas H; Briasoulis E; Vourli G; Petsas T; Xiros N; Kalofonos HP;
Anticancer Res; 2008; 28(5B):2913-20. PubMed ID: 19031934
[TBL] [Abstract][Full Text] [Related]
9. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
10. The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Polizzotto MN; Tam CS; Milner A; Januszewicz EH; Prince HM; Westerman D; Wolf MM; Seymour JF
Cancer; 2006 Aug; 107(4):773-80. PubMed ID: 16847886
[TBL] [Abstract][Full Text] [Related]
11. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer.
Jenkins P; Elyan S; Freeman S
Eur J Cancer; 2007 Feb; 43(3):544-8. PubMed ID: 17169553
[TBL] [Abstract][Full Text] [Related]
12. Encouraging results in older patients receiving chemotherapy: a retrospective analysis of treatment guideline adherence in daily practice.
Heijmen L; van Laarhoven HW; Punt CJ; van den Hurk D; van der Drift MA; Ottevanger PB; Timmer-Bonte JN
Geriatr Gerontol Int; 2012 Jan; 12(1):80-5. PubMed ID: 21883785
[TBL] [Abstract][Full Text] [Related]
13. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
[TBL] [Abstract][Full Text] [Related]
14. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.
Rajan SS; Lyman GH; Carpenter WR; Stearns SC
Breast Cancer Res Treat; 2011 Jun; 127(2):511-20. PubMed ID: 20976544
[TBL] [Abstract][Full Text] [Related]
16. Greater risks of chemotherapy toxicity in elderly patients with cancer.
Repetto L
J Support Oncol; 2003; 1(4 Suppl 2):18-24. PubMed ID: 15346996
[TBL] [Abstract][Full Text] [Related]
17. Relative dose intensity--improving treatment and outcomes in early-stage breast cancer: a retrospective study.
Griffin DA; Penprase B; Klamerus JF
Oncol Nurs Forum; 2012 Nov; 39(6):E459-67. PubMed ID: 23107859
[TBL] [Abstract][Full Text] [Related]
18. Managing hematologic toxicities.
Capo G; Waltzman R
J Support Oncol; 2004; 2(1):65-79. PubMed ID: 15330374
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer and treatment in elderly patients: the Achilles Study.
Provencio M; Camps C; Alberola V; Massutti B; Viñolas N; Isla D; Dómine M; Millán I; Cobo M; Rosell R
Lung Cancer; 2009 Oct; 66(1):103-6. PubMed ID: 19193470
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
Lyman GH; Lalla A; Barron RL; Dubois RW
Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
